Abstrakt

Przypisy

• 1. Ackler S., Mitten M.J., Chen J., Foster K., Jin S., Philips D.C.,Schlessinger S., Wang B., Leverson J.D., Boghaert E.N.: Navitoclax(abt-263) and bendamustine +/- rituxymab induce enhance clinicof non-Hodkin’slymphoma tumours in vivo. Br. J. Pharmacol.,2012; 167: 881-891
  Google Scholar
• 2. Alonso R., López-Guerra M., Upshaw R., Bantia S., Smal C.,Bontemps F., Manz C., Mehrling T., Villamor N., Campo E., MontserratE., Colomer D.: Forodesine has high antitumor activity inchronic lymphocytic leukemia and activates p53-independent mitochondrialapoptosis by induction of p73 and BIM. Blood, 2009;114: 1563-1575
  Google Scholar
• 3. Bergmann M.A., Goebeler M.E., Herold M., Emmerich B., WilhelmM., Ruelfs C., Boening L., Hallek M.J.: Efficacy of bendamustinein patients with relapsed or refractory chronic lymphocyticleukaemia: results of phase I/II study of the German CLL StudyGroup. Haematologica, 2005; 90: 1357-1364
  Google Scholar
• 4. Caligaris-Cappio F., Ghia P.: Novel insights in chronic lymphocyticleukemia: are we getting closer to understanding thepathogenesis of the disease? J. Clin. Oncol., 2008; 26: 4497-4503
  Google Scholar
• 5. Chow K.U., Boehrer S., Geduldig K., Krapohl A., Hoelzer D.,Mitrou P.S., Weidmann E.: In vitro induction of apoptosis of neoplasticcells in low-grade non-Hodgkin’s lymphoma using combinationof established cytotoxic drugs with bendamustine. Haematologica,2001; 86: 485-493
  Google Scholar
• 6. Chow K.U., Sommerlad W.D., Boehrer S., Schneider B., SeipeltG., Rummel Hoelzer D., Mitrou P.S., Weidmann E.: Anti-CD20 antibody(IDEC-C2B8 rituximab) enhances efficacy of cytotoxic drugson neoplastic lymphocytes in vitro: role of cytokines, complement,and caspases. Haematologica, 2002; 87: 33-43
  Google Scholar
• 7. Darwish M., Burke J.M., Hellriegel E., Robertson P. Jr., PhillipsL., Ludwig E., Munteanu M.C., Bond M.: An evaluation of thepotential for drug-drug interactions between bendamustine andrituximab in indolent non-Hodgkin lymphoma and mantle celllymphoma. Cancer Chemother. Pharmacol., 2014; 73: 1119-1127
  Google Scholar
• 8. Di Gaetano N., Cittera E., Nota R., Vecchi A., Grieco V., ScanzianiE., Botto M., Introna M., Golay J.: Complement activation determinesthe therapeutic activity of rituximab in vivo. J.Immunol.2003; 171: 1581-1587
  Google Scholar
• 9. Dighiero G., Hamblin T.J.: Chronic lymphocytic leukemia. Lancet,2008; 371: 1017-1029
  Google Scholar
• 10. El-Mabhouh A.A., Ayres M.L., Shpall E.J., BaladandayuthapaniV., Keating M.J., Wierda W.G., Gandhi V.: Evaluation of bendamustinein combination with fludarabine in primary chronic lymphocyticleukemia cells. Blood, 2014; 123: 3780-3789
  Google Scholar
• 11. Fischer K., Cramer P., Busch R., Stilgenbauer S., Bahlo J., SchweighoferC.D., Böttcher S., Staib P., Kiehl M., Eckart M.J., KranzG., Goede V., Elter T., Bühler A., Winkler D., et al.: Bendamustinecombined with rituximab in patients with relapsed and/or refractorychronic lymphocytic leukemia: a multicenter phase II trial ofthe German Chronic Lymphocytic Leukemia Study Group. J. Clin.Oncol., 2011; 29: 3559-3566
  Google Scholar
• 12. Franiak-Pietryga I., Maciejewski H., Wolowiec D., SalagackaA., Blonski J.Z., Janus A., Kotkowska A., Wawrzyniak E., GhiaP., Mirowski M., Robak T., Korycka-Wolowiec A.: Changes in theapoptotic gene expression profile in CLL patients treated withrituximab combined with cladribine and cyclophosphamide-preliminaryresults. Leuk. Res., 2012; 36: 1134-1140
  Google Scholar
• 13. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F.,Dighiero G., Döhner H., Hillmen P., Keating M.J., Montserrat E.,Rai K.R., Kipps T.J.: Guidelines for the diagnosis and treatment ofchronic lymphocytic leukemia: a report from the InternationalWorkshop on Chronic Lymphocytic Leukemia updating the NationalCancer Institute-Working Group 1996 guidelines. Blood,2008; 111: 5546-5556
  Google Scholar
• 14. Knauf W.U., Lissichkov T., Aldaoud A., Liberati A., LoscertalesJ., Herbrecht R., Juliusson G., Postner G., Gercheva L., Goranov S.,Becker M., Fricke H.J., Huguet F., Del Giudice I., Klein P., et al.: PhaseIII randomized study of bendamustine compared with chlorambucilin previously untreated patients with chronic lymphocyticleukemia. J. Clin. Oncol., 2009; 27: 4378-4384
  Google Scholar
• 15. Köppler H., Fuss H., Hurtz H.J., Knigge O., Losem C., ReschkeD., Schmitz S., Weide R., Weiß J., Hallek M.: Bendamustineplus mitoxantrone for relapsed/refractory chronic lymphocyticleukaemia (CLL): results of a multicentre phase II study of theGerman CLL Study Group (GCLLSG). Br. J. Haematol., 2012; 158:238-241
  Google Scholar
• 16. Korycka-Wolowiec A., Robak T.: Pahramocokinetic evaluationand therapeutic activity of bendamustine in B-cell lymphoid malignancies.Expert Opin. Drug Metab. Toxicol., 2012; 8: 1455-1468
  Google Scholar
• 17. Leoni L.M., Bailey B., Reifert J., Bendall H.H., Zeller R.W., CorbeilJ., Elliott G., Niemeyer C.C.: Bendamustine (Treanda) displaysa distinct pattern of cytotoxicity and unique mechanism featurescompared with other alkylating agent. Clin. Cancer Res., 2008;14: 309-317
  Google Scholar
• 18. Niederle N., Megdenberg D., Balleisen L., Heit W., Knauf W.,Weiß J., Freier W., Hinke A., Ibach S., Eimermacher H.: Bendamustinecompared to fludarabine as second-line treatment in chroniclymphocytic leukemia. Ann. Hematol., 2013; 92: 653-660
  Google Scholar
• 19. Owen J.S., Melhem M., Passarell J.A., d’Andrea D., Darwish M.,Kahl B.: Bendamustine pharmacokinetic profile and exposure–response relationship in patients with indolent non-Hodgkin’slymphoma. Cancer Chemother. Pharmacol., 2010; 66: 1039-1049
  Google Scholar
• 20. Pedersen I.M., Buhl A.M., Klausen P., Geisler C.H., JurlanderJ.: The chimeric anti-CD20 antibody rituximab induces apoptosisin B-cell chronic lymphocytic leukemia cells through a p38 mitogenactivated protein-kinase-dependent mechanism. Blood,2002; 99: 1314-1319
  Google Scholar
• 21. Robak T.: Novel monoclonal antibodies for the treatment ofchronic lymphocytic leukemia. Curr. Cancer Ther. Rev., 2008; 8:156-171
  Google Scholar
• 22. Roué G., López-Guerra M., Milpied P., Pérez-Galán P., VillamorN., Montserrat E., Campo E., Colomer D.: Bendamustine iseffective in p53-deficient B-cell neoplasms and requires oxidativestress and caspase-independent signaling. Clin. Cancer Res.,2008; 14: 6907-6915
  Google Scholar
• 23. Rummel M.J., Al-Batran S.E., Kim S.Z.: Bendamustine plusrituximab is effective and has a favorable toxicity profile in thetreatment of mantle cell and low-gradenon-Hodgkin’s lymphoma.J. Clin. Oncol., 2005; 23: 3383-3389
  Google Scholar
• 24. Rummel M.J, Chow K.U, Hoelzer D., Mitrou P.S., Weidmann E.:In vitro studies with bendamustine: enhanced activity in combinationwith rituximab. Semin. Oncol., 2002; 29 (4 Suppl 13): 12-14
  Google Scholar
• 25. Schmidt-Hieber M., Busse A., Reufi B., Knauf W., Thiel E., BlauI.W.: Bendamustine, but not fludarabine, exhibits a low stem celltoxicity in vitro. J. Cancer Res. Clin. Oncol., 2009; 135: 227-234
  Google Scholar
• 26. Schwanen C., Hecker T., Hubinger G., Wolfle M., Rittgen W.,Bergmann L., Karakas T.: In vitro evaluation of bendamustine inducedapoptosis in B-chronic lymphocytic leukemia. Leukemia,2002; 16: 2096-2105
  Google Scholar
• 27. Tageya N.: Bendamustine: safety and efficacy of use in the management.Clin. Med. Insights Oncol., 2011; 5: 145-156
  Google Scholar
• 28. Ujjani C., Cheson B.D.: Bandamustine in chronic lymphocytic leukemia and non-Hodgkin lymphoma. Expert Rev. Anticancer.Ther., 2010; 10: 1353-1365
  Google Scholar
• 29. Van Meerten T., van Rijn R.S., Hol S., Hagenbeek A., EbelingS.B.: Complement-induced cell death by rituximab depends onCD20 expression level and acts complementary to antibody-dependentcellular cytotoxicity. Clin. Cancer Res., 2006; 12: 4027-4035
  Google Scholar
• 30. Zaborowska A., Cebula-Obrzyt B., Franiak-Pietryga I., BłońskiJ.Z., Smolewski P., Robak T., Korycka-Wołowiec A.: The influenceof bendamustine used either alone or in combination with purinenucleoside analogues on the viability and apoptosis of chroniclymphocytic leukemia cells in vitro. Acta Haematol. Polonica,2009; 40: 887-898
  Google Scholar
• 31. Ziolkowska E., Franiak-Pietryga I., Cebula-Obrzut B., BłonskiJ.Z., Robak T., Smolewski P., Korycka-Wolowiec A.: Type of seruminfluences the rituximab dependent cytotoxicity and apoptosisof chronic lymphocytic leukemia cells in vitro. Postępy Hig. Med.Dośw., 2012; 66: 730-738
  Google Scholar

Pełna treść artykułu